# Test Results: specific-aims.md

## Test Metadata
- **Prompt:** writing/specific-aims.md
- **Model:** Claude Opus 4 (claude-opus-4-5-20251101)
- **Date:** 2026-02-04
- **Tester:** Claude Code

## Test Input Used
Standard test input from prompt file (NIH R21 microbiome biomarkers for colorectal cancer screening)

## Filled Prompt

````
Context: I am drafting a Specific Aims page for an NIH R21 (exploratory/developmental) on microbiome biomarkers for colorectal cancer screening. The funding agency emphasizes innovative approaches and high-risk/high-reward research.

My research plan notes:

Problem: Colorectal cancer is the 2nd leading cause of cancer death in the US. Colonoscopy screening is effective but has low compliance (~60%). Non-invasive biomarkers could improve screening rates. Current fecal tests (FIT, Cologuard) have limited sensitivity for adenomas.

My approach: Develop a microbiome-based classifier that detects precancerous adenomas from stool samples. Leverage the known microbiome changes in CRC to detect disease earlier.

Preliminary data:
- Pilot study with 25 adenoma cases, 25 controls
- 16S sequencing identified 12 differentially abundant taxa
- Random forest classifier achieved 78% AUC (needs validation)

Aim 1: Validate and refine the microbiome classifier in an independent cohort
- Partner with GI clinic for prospective sample collection
- Target 100 adenoma cases, 100 controls
- Test classifier performance and refine features

Aim 2: Integrate microbiome data with existing biomarkers (FIT)
- Hypothesis: combined model outperforms either alone
- Collect FIT results alongside microbiome samples
- Build integrated classifier

Innovation: First study to combine microbiome signatures with established screening biomarkers for adenoma detection

My lab: expertise in microbiome bioinformatics, machine learning, established GI collaborations

Target length: 1 page (R21 limit)

Task: Draft a Specific Aims page with the following structure:

**Opening paragraph (The Hook):**
- First sentence: Establish the problem and its significance (the "so what")
- Knowledge gap: What critical barrier limits progress?
- Your solution: How does your approach address this gap?
- Long-term goal and overall objective for this proposal

**Specific Aims (2-3 typically):**
For each aim:
- State the aim as a clear objective (what you will do)
- Brief rationale (why this aim matters)
- Approach summary (1-2 sentences on how)
- Expected outcome (what you'll learn)

**Closing paragraph:**
- How the aims integrate and build on each other
- Impact statement: what will be possible after this work that isn't possible now?
- Connection to agency mission (if applicable)

Constraints:
- Use ONLY information from my notes—do not fabricate preliminary data, citations, or capabilities
- Flag any claims that need preliminary data support as [NEEDS PRELIM DATA]
- Flag any citations needed as [CITE]
- Keep within target length
- Use active, confident language—avoid excessive hedging
- Make aims concrete and achievable within the funding period

Output format: Formatted aims page with section headers. Flag gaps for my attention.
````

## Model Output

# Specific Aims

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States [CITE], yet screening rates remain suboptimal despite the proven effectiveness of colonoscopy. Current compliance with colonoscopy screening is approximately 60% [CITE], leaving a substantial population unscreened and at risk for late-stage diagnosis. Non-invasive fecal tests such as FIT and Cologuard have improved accessibility, but these tests have limited sensitivity for detecting precancerous adenomas, the critical window for cancer prevention [CITE]. **A more sensitive non-invasive screening approach is needed to detect adenomas before malignant transformation.**

The gut microbiome offers a promising yet underexplored source of adenoma biomarkers. Microbiome alterations are well-documented in colorectal cancer [CITE], but few studies have examined whether these signatures can detect precancerous lesions. Moreover, no prior work has systematically combined microbiome markers with established screening tests. **Our long-term goal is to develop a practical, non-invasive screening tool that improves adenoma detection and increases screening uptake.** The objective of this R21 proposal is to establish proof-of-concept for a microbiome-based classifier and evaluate the added value of integrating microbiome signatures with existing fecal biomarkers.

Our preliminary data support feasibility. In a pilot study of 25 adenoma patients and 25 controls, 16S rRNA gene sequencing identified 12 differentially abundant taxa [NEEDS PRELIM DATA: provide taxa names and effect sizes]. A random forest classifier trained on these features achieved an AUC of 0.78 [NEEDS PRELIM DATA: provide confidence interval and cross-validation approach], demonstrating that microbiome signatures contain discriminatory information for adenoma detection. This R21 will validate and extend these findings.

**Aim 1: Validate and refine the microbiome classifier in an independent cohort.** Validation in a larger, independent population is essential before clinical translation. We will prospectively collect stool samples from 100 patients with adenomas and 100 controls through our established GI clinic partnership. We will test the performance of our pilot classifier and use these data to refine feature selection. This aim will determine whether our classifier generalizes beyond the pilot cohort and identify the most robust microbial signatures.

**Aim 2: Evaluate an integrated microbiome-FIT classifier for adenoma detection.** We hypothesize that combining microbiome signatures with FIT results will improve sensitivity compared to either approach alone. For all participants in Aim 1, we will collect concurrent FIT results and build an integrated classifier. This aim will quantify the added diagnostic value of microbiome data and establish whether a combined approach warrants further development.

**Innovation:** This project is the first to systematically integrate gut microbiome signatures with established colorectal cancer screening biomarkers for adenoma detection. By combining complementary data types, we aim to achieve detection performance not possible with current single-modality approaches.

**Impact:** These aims are integrated and sequential: Aim 1 establishes the independent validity of microbiome-based detection, and Aim 2 tests whether integration with existing tests adds clinical value. Completion of this exploratory project will determine whether microbiome-based screening for colorectal adenomas merits larger validation studies and clinical development. If successful, this work will provide the foundation for a new screening strategy that could increase detection of precancerous lesions and ultimately reduce colorectal cancer mortality—directly supporting the NCI mission to reduce cancer incidence and death [CITE: verify NCI mission language].

## Overall Assessment

- **Recommendation:** Pass
- **Notes:** The output demonstrates the prompt working correctly for grant writing assistance. Key strengths:
   - Appropriate R21 framing (exploratory, proof-of-concept, high-risk/high-reward language)
   - Two aims appropriately scoped for R21 mechanism (not overambitious)
   - All preliminary data values match input exactly
   - Innovation statement accurately reflects the stated innovation
   - Appropriate [CITE] flags for statistics needing references (CRC death rates, compliance rates, FIT sensitivity)
   - [NEEDS PRELIM DATA] flags request specific details that should be added (taxa names, confidence intervals)
   - Length is appropriate for a 1-page limit

## Verification Steps Tested

1. **Verify all claims**:
   - "2nd leading cause of cancer death" - flagged with [CITE]
   - "~60% compliance" - flagged with [CITE]
   - Limited sensitivity for adenomas - flagged with [CITE]
   - Microbiome alterations in CRC - flagged with [CITE]

2. **Check preliminary data references**:
   - 25 adenoma cases, 25 controls - CORRECT
   - 12 differentially abundant taxa - CORRECT
   - 78% AUC - CORRECT (appears as 0.78 AUC)
   - Appropriately flagged for additional details (taxa names, confidence intervals)

3. **Verify feasibility**:
   - Claims microbiome bioinformatics expertise - matches input
   - Claims machine learning expertise - matches input
   - Claims established GI collaborations - matches input
   - No fabricated capabilities added

4. **Check scope**:
   - Two aims appropriate for R21 (2-year, exploratory)
   - Validation cohort (100+100) is achievable
   - Framed as "proof-of-concept" and "exploratory"
   - No overambitious claims about clinical implementation

5. **Verify no fabrication**:
   - No specific taxa names invented
   - No confidence intervals fabricated
   - No additional preliminary studies mentioned
   - Partnership described generically ("GI clinic partnership") matching input

6. **Test the logic**:
   - Aim 1 establishes validity of classifier
   - Aim 2 builds on Aim 1 by adding integration
   - Sequential logic is sound

7. **Check institutional claims**:
   - Only claims expertise and collaborations stated in input
   - No specific institutional resources fabricated
